-

lino Biotech exhibits its products at DxPx Conference

The company is a silver sponsor of DxPx Industry & Investor Conference

ZURICH--(BUSINESS WIRE)--lino Biotech AG, the world’s only company specialized in focal molography – an entirely new method for measuring molecular interactions in living cells or crude biological samples- is a part of the DxPx Conference as a silver sponsor and will showcase their novel products. The company is supporting the Conference, among other sponsors such as gold sponsor Roche and silver sponsors Hologic and synevo. The program of the DxPx Conference on November 16th 2021 at the Maritim Hotel in Dusseldorf, Germany, with the extended option for digital partnering from November 12th – 20th 2021, includes several panel discussions, as well as fireside chats with renowned speakers. lino Biotech will also be showcasing their products among other startups and growth companies in the accompanying exhibition.

As a sponsor of the annual flagship conference, lino Biotech provides any investor interested to meet them a complimentary for the event. “With our sponsorship, we want to promote intensive dialogue between newcomers to the industry, established companies, and investors, as we know how difficult it can be for small companies to draw attention”, says Dr. Volker Gatterdam, VP Commercial at lino Biotech.

The company will exhibit its biosensor platform and new performance data at the Industry & Investor Partnering Conference on Diagnostics, Digital Health, Precision Medicine & Life Science Tools, November 16th on-site in Dusseldorf. Investors interested in meeting the company can contact lino Biotech for tickets to access the conference.

About lino Biotech AG:

lino Biotech AG – www.lino-biotech.com - was incorporated as ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several life science family offices. lino Biotech is a life science tools company, offering biosensors and readers for complex solution analytics. The entirely new method of measuring molecular interactions enables customers from cell and gene therapy to optimize their R&D and production processes, reduce cost, and improve product quality. In the future, lino´s technology molography will also offer new applications in bioprocessing, diagnostics, and precision medicine.

Contacts

press contact
Dagmar Metzger
+49-89-3577579-0
info@wordstatt.de

lino Biotech AG


Release Versions

Contacts

press contact
Dagmar Metzger
+49-89-3577579-0
info@wordstatt.de

More News From lino Biotech AG

lino Biotech Expands Board of Directors

ZURICH--(BUSINESS WIRE)--lino Biotech AG, a spin-out from Roche Diagnostics that has developed a reagent-free method for measuring molecular interactions in living cells or crude biological samples, welcomes Dr. Matthias Essenpreis as its new board member. With his deep and long-standing knowledge as Chief Technology Officer at Roche Diagnostics, he will be a great addition for the strategic development of the company. He will complete the board of directors, alongside chairman Seppo Mäkinen, s...

lino Biotech Can Draw on Over 150 Years of Experience in Life Science, Cell Therapy and Diagnostics Thanks to Five Internationally Renowned Industry Experts

ZURICH--(BUSINESS WIRE)--lino Biotech AG is the world’s only company specialized in focal molography – an entirely new method for measuring molecular interactions in living cells or crude biological samples. The broadly patented technology offers label-free detection assays while eliminating signal disturbances due to temperature changes or non-specific binding. The company was incorporated in Zürich, Switzerland, in March 2020 with the aim to make cell therapies more cost effective and accessi...

lino Biotech closes seed financing round and showcases a novel label-free biosensor platform for innovate modern drug screening

ZURICH--(BUSINESS WIRE)--After almost a decade of initial invention and joint research on the Focal Molography technology at Roche, a leading player in the diagnostics and pharmaceutical area, and ETH Zurich as one of Europe’s most renowned research institutes, lino Biotech AG has licensed the technology to further develop and commercialize Focal Molography. The company has received 7-digit financing from lead-investors HTGF, Roche Ventures and several family offices. This broadly patented tech...
Back to Newsroom